Robbie Marcus
Stock Analyst at JP Morgan
(0.53)
# 1883
Out of 5,240 analysts
148
Total ratings
52.75%
Success rate
7.46%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
NeuroPace | Maintains: Overweight | 9 14 | 11.94 | 17.25% | 4 | Dec 17, 2024 | |
Bioventus | Upgrades: Neutral | 12 13 | 9.11 | 42.7% | 3 | Dec 17, 2024 | |
Zimmer Biomet Holdin... | Upgrades: Overweight | 125 128 | 104.73 | 22.22% | 5 | Dec 17, 2024 | |
Boston Scientific | Maintains: Overweight | 100 110 | 97.07 | 13.32% | 9 | Dec 16, 2024 | |
Insulet | Maintains: Overweight | 280 330 | 269.13 | 22.62% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 32 | 20.67 | 54.81% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 375 420 | 367.45 | 14.3% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 40 | 35.43 | 12.9% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 72 78 | 71.86 | 8.54% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 75 85 | 81.78 | 3.94% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 495 575 | 569.99 | 0.88% | 4 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 90 | 86.07 | 4.57% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 53 50 | 45.55 | 9.77% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 44 42 | 30.73 | 36.67% | 12 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 5 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 8 | 8.33 | -3.96% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 19 21 | n/a | n/a | 3 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 36 13 | 16.14 | -19.45% | 5 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 115 75 | 67.56 | 11.01% | 5 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 100 120 | 90.84 | 32.1% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 62 | 30.53 | 103.08% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 284 250 | 254.74 | -1.86% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 10 16 | 13.8 | 15.94% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 8 7 | 10.76 | -34.94% | 11 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 340 181 | 175.84 | 2.93% | 4 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 56 43 | 22.35 | 92.39% | 5 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 17 | 17.3 | -1.73% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 125 118 | 112.21 | 5.16% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 116 156 | 98.76 | 57.96% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 130 105 | 85.65 | 22.59% | 6 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | n/a | n/a | n/a | 2 | Nov 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 220 | n/a | n/a | 2 | Sep 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 6 | n/a | n/a | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 55 40 | 148.56 | -73.07% | 2 | May 5, 2020 |